Literature DB >> 23834155

Nuclear export mediated regulation of microRNAs: potential target for drug intervention.

Irfana Muqbil1, Bin Bao, Abdul Badi Abou-Samra, Ramzi M Mohammad, Asfar S Azmi.   

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs that have been recognized to regulate the expression of uncountable number of genes. Their aberrant expression has been found to be linked to the pathology of many diseases including cancer. There is a drive to develop miRNA targeted therapeutics for different diseases especially cancer. Nevertheless, reining in these short non-coding RNAs is not as straightforward as originally thought. This is in view of the recent discoveries that miRNAs are under epigenetic regulations at multiple levels. Exportin 5 protein (XPO5) nuclear export mediated regulation of miRNAs is one such important epigenetic mechanism. XPO5 is responsible for exporting precursor miRNAs through the nuclear membrane to the cytoplasm, and is thus a critical step in miRNA biogenesis. A number of studies have shown that variations in components of the miRNA biogenesis pathways, particularly the aberrant expression of XPO5, increase the risk of developing cancer. In addition to XPO5, the Exportin 1 protein (XPO1) or chromosome region maintenance 1 (CRM1) can also carry miRNA export function. These findings are supported by pathway analyses that reveal certain miRNAs as direct interaction partners of CRM1. An in depth understanding of miRNA export mediated regulatory mechanisms is important for the successful design of clinically viable therapeutics. In this review, we describe the current knowledge on the mechanisms of miRNA nuclear transport mediated regulation and propose strategies to selectively block this important mechanism in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23834155      PMCID: PMC4167361          DOI: 10.2174/1389450111314100002

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  69 in total

Review 1.  Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis.

Authors:  Thomas Braun; Mathias Gautel
Journal:  Nat Rev Mol Cell Biol       Date:  2011-06       Impact factor: 94.444

Review 2.  Adopting network pharmacology for cancer drug discovery.

Authors:  Asfar S Azmi
Journal:  Curr Drug Discov Technol       Date:  2013-06

3.  Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis.

Authors:  Derek Leaderer; Aaron E Hoffman; Tongzhang Zheng; Alan Fu; Joanne Weidhaas; Trupti Paranjape; Yong Zhu
Journal:  Int J Mol Epidemiol Genet       Date:  2010-11-25

Review 4.  Selective nuclear export mechanism of small RNAs.

Authors:  Soo Jae Lee; Chimari Jiko; Eiki Yamashita; Tomitake Tsukihara
Journal:  Curr Opin Struct Biol       Date:  2010-12-07       Impact factor: 6.809

Review 5.  Nuclear export dynamics of RNA-protein complexes.

Authors:  David Grünwald; Robert H Singer; Michael Rout
Journal:  Nature       Date:  2011-07-20       Impact factor: 49.962

6.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

7.  The nuclear export receptor XPO-1 supports primary miRNA processing in C. elegans and Drosophila.

Authors:  Ingo Büssing; Jr-Shiuan Yang; Eric C Lai; Helge Grosshans
Journal:  EMBO J       Date:  2010-04-30       Impact factor: 11.598

8.  CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

Authors:  Hiromi Inoue; Michael Kauffman; Sharon Shacham; Yosef Landesman; Joy Yang; Christopher P Evans; Robert H Weiss
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

Review 9.  MicroRNAs: key regulators of stem cells.

Authors:  Vamsi K Gangaraju; Haifan Lin
Journal:  Nat Rev Mol Cell Biol       Date:  2009-02       Impact factor: 94.444

10.  MicroRNA-mediated mRNA translation activation in quiescent cells and oocytes involves recruitment of a nuclear microRNP.

Authors:  S S Truesdell; R D Mortensen; M Seo; J C Schroeder; J H Lee; O LeTonqueze; S Vasudevan
Journal:  Sci Rep       Date:  2012-11-13       Impact factor: 4.379

View more
  22 in total

1.  Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase".

Authors:  Asfar S Azmi; Ramzi M Mohammad
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

2.  Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer.

Authors:  Kunitoshi Shigeyasu; Yoshinaga Okugawa; Shusuke Toden; C Richard Boland; Ajay Goel
Journal:  Clin Cancer Res       Date:  2016-08-23       Impact factor: 12.531

Review 3.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

4.  Intact RNA structurome reveals mRNA structure-mediated regulation of miRNA cleavage in vivo.

Authors:  Minglei Yang; Hugh C Woolfenden; Yueying Zhang; Xiaofeng Fang; Qi Liu; Maria L Vigh; Jitender Cheema; Xiaofei Yang; Matthew Norris; Sha Yu; Alberto Carbonell; Peter Brodersen; Jiawei Wang; Yiliang Ding
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

Review 5.  MicroRNA Machinery Genes as Novel Biomarkers for Cancer.

Authors:  Jing-Tao Huang; Jin Wang; Vibhuti Srivastava; Subrata Sen; Song-Mei Liu
Journal:  Front Oncol       Date:  2014-05-19       Impact factor: 6.244

6.  RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage-induced cell senescence.

Authors:  Pavol Cekan; Keisuke Hasegawa; Yu Pan; Emily Tubman; David Odde; Jin-Qiu Chen; Michelle A Herrmann; Sheetal Kumar; Petr Kalab
Journal:  Mol Biol Cell       Date:  2016-02-10       Impact factor: 4.138

Review 7.  Broad targeting of resistance to apoptosis in cancer.

Authors:  Ramzi M Mohammad; Irfana Muqbil; Leroy Lowe; Clement Yedjou; Hsue-Yin Hsu; Liang-Tzung Lin; Markus David Siegelin; Carmela Fimognari; Nagi B Kumar; Q Ping Dou; Huanjie Yang; Abbas K Samadi; Gian Luigi Russo; Carmela Spagnuolo; Swapan K Ray; Mrinmay Chakrabarti; James D Morre; Helen M Coley; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; William G Helferich; Xujuan Yang; Chandra S Boosani; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; W Nicol Keith; Alan Bilsland; Dorota Halicka; Somaira Nowsheen; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2015-04-28       Impact factor: 15.707

8.  Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Authors:  Asfar S Azmi; Yiwei Li; Irfana Muqbil; Amro Aboukameel; William Senapedis; Erkan Baloglu; Yosef Landesman; Sharon Shacham; Michael G Kauffman; Philip A Philip; Ramzi M Mohammad
Journal:  Oncotarget       Date:  2017-07-17

9.  XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Authors:  Giovanni Luca Gravina; Monica Tortoreto; Andrea Mancini; Alessandro Addis; Ernesto Di Cesare; Andrea Lenzi; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Nadia Zaffaroni; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-10-05       Impact factor: 17.388

10.  Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver.

Authors:  Qiao-Ling Xie; Yue Liu; Ying Zhu
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.